Trade PLX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Protalix BioTherapeutics, Inc. (PLX) is trading at US$2.69, down 0.37% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$191.76M. Over the past 52 weeks, PLX has traded between US$1.60 and US$3.19. On Syfe you can trade PLX with $0 commission and add it to your watchlist.
| Previous close | US$2.70 |
|---|---|
| Market cap | US$191.76M |
| P/E ratio | 26.09 |
| 52-week range | US$1.60 – US$3.19 |
| Volume | 1.22M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Protalix BioTherapeutics, Inc.
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Year: 1996
Protalix BioTherapeutics, Inc. (PLX) stock is trading at US$2.69, -0.37% from the previous close of US$2.70.
The market cap for Protalix BioTherapeutics, Inc. (PLX) stock is approximately US$191.76M.
The price-to-earnings ratio for Protalix BioTherapeutics, Inc. (PLX) is 26.09, based on the latest reported earnings.
The 52-week high for Protalix BioTherapeutics, Inc. (PLX) stock is US$3.19.
The 52-week low for Protalix BioTherapeutics, Inc. (PLX) stock is US$1.60.
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a dividend.
Stay on top of PLX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
